MX2021007536A - Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo. - Google Patents

Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.

Info

Publication number
MX2021007536A
MX2021007536A MX2021007536A MX2021007536A MX2021007536A MX 2021007536 A MX2021007536 A MX 2021007536A MX 2021007536 A MX2021007536 A MX 2021007536A MX 2021007536 A MX2021007536 A MX 2021007536A MX 2021007536 A MX2021007536 A MX 2021007536A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
crystalline
salts
organic compound
salt forms
Prior art date
Application number
MX2021007536A
Other languages
English (en)
Spanish (es)
Inventor
Shijie Zhang
Syed Altaf
Abira Ramakrishnan
Jacob Sizemore
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of MX2021007536A publication Critical patent/MX2021007536A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021007536A 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo. MX2021007536A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862784083P 2018-12-21 2018-12-21
US201962791571P 2019-01-11 2019-01-11
US201962882712P 2019-08-05 2019-08-05
PCT/US2019/067897 WO2020132471A1 (en) 2018-12-21 2019-12-20 Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
MX2021007536A true MX2021007536A (es) 2021-09-23

Family

ID=69185721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007536A MX2021007536A (es) 2018-12-21 2019-12-20 Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.

Country Status (23)

Country Link
US (2) US12297179B2 (enExample)
EP (1) EP3898597A1 (enExample)
JP (3) JP2022515239A (enExample)
KR (1) KR20220035022A (enExample)
CN (1) CN113508108B (enExample)
AU (1) AU2019403396B2 (enExample)
BR (1) BR112021012305A2 (enExample)
CA (1) CA3124401A1 (enExample)
CL (1) CL2021001640A1 (enExample)
CO (1) CO2021009309A2 (enExample)
CR (1) CR20210394A (enExample)
GE (2) GEAP202415700A (enExample)
IL (1) IL284218B1 (enExample)
JO (1) JOP20210147A1 (enExample)
MA (1) MA54541A (enExample)
MX (1) MX2021007536A (enExample)
NI (1) NI202100055A (enExample)
PE (2) PE20212197A1 (enExample)
PH (1) PH12021551495A1 (enExample)
SG (1) SG11202106526UA (enExample)
TW (1) TWI875727B (enExample)
UA (1) UA130491C2 (enExample)
WO (1) WO2020132471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211462T1 (hr) 2017-04-24 2021-12-24 Aurigene Discovery Technologies Limited Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
TWI818954B (zh) 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
US9012464B2 (en) * 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
US9360932B1 (en) 2012-08-29 2016-06-07 Intellect Motion Llc. Systems and methods for virtually displaying real movements of objects in a 3D-space by means of 2D-video capture
CN103965133B (zh) * 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
TWI818954B (zh) * 2018-02-20 2023-10-21 法商施維雅藥廠 三取代之苯并三唑衍生物的使用方法
CA3184024A1 (en) * 2020-06-24 2021-12-30 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
ES3063941T3 (en) * 2020-08-27 2026-04-21 Servier Lab Combinations of a dhodh inhibitor and r-chop therapy for the treatment of diffuse large b-cell lymphoma, mantle cell lymphoma and burkitt lymphoma

Also Published As

Publication number Publication date
NI202100055A (es) 2021-12-01
BR112021012305A2 (pt) 2021-10-05
GEAP202415700A (en) 2024-05-13
JP7749080B2 (ja) 2025-10-03
TWI875727B (zh) 2025-03-11
CA3124401A1 (en) 2020-06-25
CN113508108B (zh) 2024-12-24
AU2019403396A1 (en) 2021-07-08
CL2021001640A1 (es) 2022-06-03
CN113508108A (zh) 2021-10-15
JOP20210147A1 (ar) 2023-01-30
KR20220035022A (ko) 2022-03-21
US12297179B2 (en) 2025-05-13
IL284218A (en) 2021-08-31
WO2020132471A1 (en) 2020-06-25
US20250270175A1 (en) 2025-08-28
PH12021551495A1 (en) 2022-03-07
JP2026001058A (ja) 2026-01-06
SG11202106526UA (en) 2021-07-29
UA130491C2 (uk) 2026-03-04
CO2021009309A2 (es) 2021-10-29
WO2020132471A8 (en) 2020-08-06
PE20212197A1 (es) 2021-11-16
PE20260309A1 (es) 2026-02-11
AU2019403396B2 (en) 2024-12-12
GEP20247683B (en) 2024-10-28
EP3898597A1 (en) 2021-10-27
MA54541A (fr) 2022-03-09
JP2024161431A (ja) 2024-11-19
US20220055995A1 (en) 2022-02-24
TW202039448A (zh) 2020-11-01
JP2022515239A (ja) 2022-02-17
IL284218B1 (en) 2026-01-01
CR20210394A (es) 2021-12-13

Similar Documents

Publication Publication Date Title
NI202100055A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CY1121549T1 (el) Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων
MX2020005348A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1-car bonil)fenil)quinolin-8-sulfonamida.
MX2020007265A (es) Derivados de rapamicina.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
CU20180152A7 (es) Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
EA201690094A1 (ru) Ингибиторы syk
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
MX2017013629A (es) Metodos para mejora hidraulica de cultivos.
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
CL2020000376A1 (es) Compuesto pentacíclico.
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
BR112017016819A2 (pt) compostos de diaza-benzofluorantreno